752243-41-7

Upstream product

• 1450914-73-4 C₃₃H₃₉N₃O₆S 
• 7304-32-7 2-fluoro-5-nitrobenzoic acid 
• 3963-62-0 2,2-Diphenylethylamine 
• 752243-43-9 1-[4-fluoro-3-(morpholine-4-carbonyl)-benzenesulfonyl]-piperidine-4-carboxylic acid 
• 752243-42-8 (5-amino-2-fluoro-phenyl)-morpholin-4-yl-methanone 
• 709-46-6 2-fluoro-5-nitrobenzoyl chloride 

Downstream Products

• 312722-59-1 4-{2-[(2,2-diphenyl-ethyl)-amino]-5-{[4-[4-(1-methyl-ethyl)-piperazin-1-yl-carbonyl]-piperidin-1-yl]-sulfonyl}-benzoyl}-morpholine 

Relevant academic research and scientific papers

BRADYKININ RECEPTOR ANTAGONISTS

The invention relates to sulfonyl amine derivatives of formula IA wherein R5A, X1, X2, R9 and R10 are as defined herein, which derivatives are useful as bradykinin B1 receptor antagonists.

Potent and orally bioavailable non-peptide antagonists at the human bradykinin B1 receptor based on a 2-alkylamino-5-sulfamoylbenzamide core

The bradykinin B1 receptor is rapidly induced after inflammation or tissue trauma and appears to play an important role in the maintenance of hyperalgesia in inflammatory conditions. Here, we describe the optimization process to identify novel,